



Phytochemicals Activity of *Bacopa monnieri* (L.) pennel.- A brief review

Priyanka Dubey¹, Ravi Upadhyaya², Anil Prakash¹

¹ Department of Microbiology, UTD, B.V.V. Bhopal, Madhya Pradesh, India

² Department of Botany, Govt. NMV Narmadapuram, Madhya Pradesh, India

Abstract

This review brings out research with phytochemicals associated with low-toxic cognitive enhancing actions of *Bacopa monnieri*, a medicinal Ayurvedic herb. *Bacopa monnieri* is traditionally used for a variety of ailments, but is best known as a nerve tonic and memory enhancer. Several animal and in vitro studies have been conducted, which have found evidence of several potential medicinal properties. Several randomized, double-blind, placebo-controlled trials have confirmed *Bacopa monnieri* nootropic utility in humans. There is also evidence of possible attenuation of dementia, Parkinson's disease, and epilepsy. Current evidence suggests that *Bacopa monnieri* acts through the following mechanisms—anti-oxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β -amyloid reduction, in cerebral blood flow growth, and neurotransmitter modulation (acetylcholine [ACh], 5-hydroxytryptamine [5-HT], dopamine [DA]). *Bacopa monnieri* appears to exhibit low toxicity in model organisms and humans; However, long-term studies of toxicity in humans have not yet been conducted. This review will integrate phytochemicals in neuroscience with behavioral research.

Keywords: *Bacopa monnieri* (L.), phytochemicals, Cognitive Enhancement

Introduction

The milieu of nootropic phytochemicals found within *Bacopa monnieri*, primarily triperpenoid saponins called bacosides, exhibit minimal observable adverse effects at standard dosages. *Bacopa monnieri* demonstrates anti-oxidant, (Tripathi *et al.*, 1996) hepatoprotective, (Ghosh *et al.*, 2007) and neuroprotective activity. Emerging research demonstrates several mechanisms of action—acetylcholinesterase inhibition, choline acetyltransferase activation, β -amyloid reduction, increased cerebral blood flow, and monoamine potentiation.

Bacopa monnieri, commonly known as Brahmi or water hyssop, is a perennial herb native to wetlands in Asia, particularly in India, Nepal, Sri Lanka, and China. It has a long history of use in traditional Ayurvedic medicine for enhancing cognitive function, improving memory, and promoting longevity. The herb is characterized by its succulent leaves and small white flowers and typically grows in marshy areas, along the edges of ponds, and in damp soil. Here are some key points about *Bacopa monnieri*.

In a 90-day oral administration trial in rats, *Bacopa monnieri* exhibited a no-observed adverse effect level (NOAEL) of 500 mg/kg and a median lethal dose (LD50) of 2400 mg/kg (Tripathi *et al.*, 1996). The standard experimental human dose is between 150 and 3000 mg equivalent per day. The most common clinical side effect of *Bacopa monnieri* is mild gastrointestinal upset, but long-term clinical trials are lacking. Several research groups formulate bacoside-standardized *Bacopa monnieri* extract for clinical use, and the herb is widely used in India, the United States, and Australia. *Bacopa monnieri* has been applied in rodents and cell culture for the following uses, which will not be detailed in this review: anti-convulsant (Mathew *et al.*, 2010^[16], 2011^[15]; Khan, Krishnakumar and Paulose, 2008), anti-depressant (Sairam *et al.*, 2002), analgesic (Abbas *et al.*, 2011^[1]; Vohora *et al.*, 2012;

Afjalus *et al.*, 2012)^[2], anti-inflammatory (Jain *et al.*, 1994), anti-microbial (Azad *et al.*, 2012)^[4], anti-ulcerogenic (Sairam *et al.*, 2001) /anti-H. Pylori (Goel *et al.*, 2003), anxiolytic (Bhattacharya and Ghosal, 2001), adaptogenic (Bhatia *et al.*, 2003; Chowdhuri *et al.*, 2002), anti-neoplastic (Deb *et al.*, 2008; Elangovan *et al.*, 1995), hepatoprotective (Ghosh *et al.*, 2007), immunostimulatory (Yamada *et al.*, 2011; Samiulla, Prashanth and Amit 2001; Russo and Borrelli, 2005) Past reviews have focused on the broad therapeutic uses of *Bacopa monnieri*, including the above uses. This review will elucidate the neuropharmacological mechanisms underlying the nootropic effects of the herb, summarize pre-clinical and clinical studies, outline putative mechanisms of action, and address issues of toxicity.

Chemical Constituents

Bacopa monnieri contains a variety of bioactive compounds, including alkaloids (such as brahmine and herpestine), saponins (including bacosides A and B), flavonoids, triterpenoid saponins, betulinic acid derivatives, polyphenols, sterols, and others (Sivaramakrishna *et al.*, 2005; Garai *et al.*, 2009; Chakravarty *et al.*, 2003; Chakravarty *et al.*, 2008; Deepak *et al.*, 2007). , Rastogi *et al.* 2012^[28, 29] found this bacoside profile—bacopaside I (5.37%), bacoside A3 (5.59%), bacopaside II (6.9%), bacopasaponin C isomer (7.08%), and bacopasaponin C. These compounds are responsible for its pharmacological activities.

Cognitive Enhancement: *Bacopa monnieri* is renowned for its cognitive-enhancing properties. It has been traditionally used to improve memory, concentration, learning, and overall cognitive function. Clinical studies have demonstrated its effectiveness in enhancing memory retention, speed of information processing, and cognitive performance, particularly in elderly individuals (Munch *et al.*, 2002, Pratico D. Delanty, 2000; Reddy, 2007, Shankar

et al., 2008, Francis *et al.*, 1999). Despite some controversy, cigarette smoking appears to increase dementia risk (Rusanen *et al.*, 2011^[31]; Cataldo, Prochaska and Glantz, 2010)^[5].

Neuroprotective Effects: The herb exhibits neuroprotective effects by reducing oxidative stress, inflammation, and neuronal damage in the brain. It may help protect against neurodegenerative diseases such as Alzheimer's and Parkinson's by preserving neuronal function and promoting nerve cell regeneration. Adaptogens enable the body to better cope with the deleterious mental and physical consequences of stress. *Eleutherococcus senticosus* (Siberian ginseng), *Rhodiola rosea*, and *Panax ginseng* are classic adaptogens. Others include *Ocimum sanctum* (Sweet Holy Basil or Tulsi), *Withania somnifera* (Ashwagandha), *Astragalus propinquus*, *Ganoderma lucidum* (Reishi mushroom), and many others (Winston and Maimes, 2007). Sheikh *et al.*, 2007 evaluated *Bacopa monnieri* adaptogenic effect in acute stress and chronic unpredictable stress-induced fluctuations of plasma corticosterone and monoamines in the rat cortex and hippocampus. Charles *et al.*, 1999 found *Bacopa monnieri* extract up-regulated tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression in rats.

Antioxidant and Anti-inflammatory Properties: *Bacopa monnieri* possesses potent antioxidant and anti-inflammatory properties, which contribute to its neuroprotective effects and overall health benefits. It scavenges free radicals, reduces oxidative damage to cells, and alleviates inflammation, thereby protecting against various chronic diseases and promoting longevity.

Anxiolytic and Antidepressant Effects: *Bacopa monnieri* has been reported to have anxiolytic and antidepressant properties, helping to reduce anxiety, stress, and depression. It may modulate neurotransmitter levels in the brain and promote feelings of calmness and well-being.

Other Health Benefits: In addition to its cognitive and neurological effects, *Bacopa monnieri* is also believed to have various other health benefits, including improving cardiovascular health, enhancing digestive function, and boosting immunity.

Bacopa monnieri is available in various forms, including capsules, tablets, powders, and liquid extracts. It is often used as a dietary supplement for cognitive support and overall well-being. However, as with any herbal supplement, it's essential to consult with a healthcare professional before starting *Bacopa monnieri*, especially if you have any underlying medical conditions or are taking medications.

A review of phytochemicals and activity of *Bacopa monnieri* Linn. would likely delve into the diverse array of bioactive compounds found within this medicinal herb and their associated biological activities. *Bacopa monnieri*, also known as Brahmi or water hyssop, is a traditional Ayurvedic herb renowned for its cognitive-enhancing properties. Here's an overview:

Alkaloids: *Bacopa monnieri* contains alkaloids such as brahmine and herpestine, which have been found to possess neuroprotective and memory-enhancing effects. These

alkaloids are believed to play a role in improving cognitive function and protecting against neurodegenerative diseases.

Saponins: The herb contains saponins, including bacosides A and B, which are considered the primary active compounds responsible for its cognitive benefits. Bacosides have been shown to enhance neuronal communication, improve memory formation, and exhibit antioxidant properties, thus protecting against oxidative stress-induced neuronal damage.

Flavonoids: *Bacopa monnieri* is rich in flavonoids, such as apigenin and luteolin, which possess antioxidant and anti-inflammatory properties. These compounds may contribute to the herb's neuroprotective effects by reducing inflammation and oxidative stress in the brain.

Triterpenoid saponins: These compounds are also present in *Bacopa monnieri* and have been found to exhibit various pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects.

Betulinic acid derivatives: Recent studies have identified betulinic acid derivatives in *Bacopa monnieri* with potential neuroprotective and antidepressant properties.

Polyphenols: *Bacopa monnieri* contains polyphenolic compounds like catechins and epicatechins, which have antioxidant properties and may contribute to the herb's overall neuroprotective effects.

Other compounds: *Bacopa monnieri* also contains other phytochemicals such as sterols, triterpenoids, and betulinic acid, which may contribute to its pharmacological activities. In terms of activities, *Bacopa monnieri* has been extensively studied for its various biological effects, including:

Cognitive enhancement: *Bacopa monnieri* has been traditionally used to improve memory, concentration, and learning abilities. Clinical studies have supported its efficacy in enhancing cognitive function, particularly memory and attention.

Neuroprotection: The herb exhibits neuroprotective effects by reducing oxidative stress, inflammation, and neuronal damage. It may help protect against neurodegenerative diseases such as Alzheimer's and Parkinson's. (De Grey, 1999) by degrading ligands, peroxidizing lipids, disrupting metabolic pathways, denaturing proteins, and breaking DNA strands (Maxwell, 1995). The brain is especially susceptible to OS because it is metabolically active, possesses high levels of pro-oxidant iron, and is composed of unsaturated lipids (prone to lipid peroxidation). (Arivazhagan *et al.*, 2002) Furthermore, the blood-brain barrier prevents many exogenous anti-oxidants from quenching reactive oxygen species (ROS) in the brain (Gilgun-Sherki, Melamed and Offen, 2001).

Antioxidant activity: *Bacopa monnieri* is a potent antioxidant, scavenging free radicals and protecting cells from oxidative damage (Kregel and Zhang, 2007). This antioxidant activity contributes to its neuroprotective effects and overall health benefits (Valko *et al.*, 2007).

Anti-inflammatory properties: The herb has been shown to possess anti-inflammatory effects, which may help alleviate

inflammation in the brain and reduce the risk of neurodegenerative diseases.

Anxiolytic and antidepressant effects: *Bacopa monnieri* has been reported to have anxiolytic and antidepressant properties, which may be attributed to its ability to modulate neurotransmitter levels and reduce stress and anxiety. Overall, *Bacopa monnieri* is a rich source of phytochemicals with diverse pharmacological activities, particularly in improving cognitive function and protecting against neurodegenerative diseases. Its traditional use in Ayurvedic medicine is supported by modern scientific research, making it a promising candidate for further investigation and development as a natural remedy for cognitive disorders and neurodegenerative conditions.

Anbarasi *et al.*, 2006 assessed the neuroprotective role of bacoside A against OS in the brains of rats exposed to cigarette smoke by measuring concentrations of enzymatic and non-enzymatic anti-oxidants as well as trace elements. The researchers administered 10 mg/kg aqueous bacoside A gavage daily and found that *Bacopa monnieri* significantly increased brain levels of glutathione, vitamin C, vitamin E, and vitamin A in rats exposed to cigarette smoke (perhaps an anti-oxidant conservation effect). Bacoside A administration increased the activities of superoxide dismutase (SOD), catalase, GPx, and GSR. As a result, the levels of glutathione (primary endogenous anti-oxidant conjugate) in the brain were significantly increased as well. The researchers found that cigarette smoke depletes zinc and selenium levels in the brain, which is especially problematic because zinc is a SOD co-factor and selenium is a GPx co-factor. Administration of bacoside A also restored zinc and selenium levels. In a related study, Anbarasi *et al.*, 2005 also showed that 10 mg/kg aqueous gavage administration of bacoside A inhibited lipid peroxidation, improved the activities of adenosine triphosphatases (ATPases), and maintained ionic equilibrium in the brains of cigarette smoke-exposed rats.

Conclusion

Bacopa monnieri demonstrates immense potential in the amelioration of cognitive disorders, as well as prophylactic reduction of oxidative damage, NT modulation, and cognitive enhancement in healthy people. Biomedical research on *Bacopa monnieri* is still in its infancy, but preliminary results such as these have begun to open the research floodgates. It is critical that much longer-term studies be conducted *Bacopa monnieri* in combination with other substances, as is prescribed by the Ayurvedic system, may result in synergistic effects and should also be investigated. The social implications of cognition-enhancing drugs are promising but must be appropriately tempered with ethical consideration as researchers enter the brave new world of neural enhancement.

References

1. Abbas M, Subhan F, Mohani N, Rauf K, Ali G, Khan M. The involvement of opioidergic mechanisms in the activity of *Bacopa monnieri* extract and its toxicological studies. *Afr J Pharm Pharmacol*,2011;5:1120–1124.
2. Afjalus S, Chakma N, Rahman M, Salahuddin M, Kumar S. Assessment of analgesic, antidiarrhoeal and cytotoxic activity of ethanolic extract of the whole plant of *Bacopa monnieri* linn. *IRJP*,2012;3(10) online publication.
3. Ahirwar S, Tembhre M, Gour S, Namdeo A. Anticholinesterase efficacy of *Bacopa monnieri* against the brain regions of rat. *Asian J Exp Sci*,2012;26:65–70.
4. Azad A, Awang M, Rahman M, Akter S. Biological and pre-clinical trial evaluation of a local medicinal plant *Bacopa monnieri* (L.). *IJCRR*,2012;4:92–99.
5. Cataldo J, Prochaska J, Glantz S. Cigarette smoking is a risk factor for Alzheimer's Disease: An analysis controlling for tobacco industry affiliation. *J Alzheimers Dis*,2010;19:465–480.
6. Charles PD, Ambigapathy G, Geraldine P, Akbarsha MA, Rajan KE. *Bacopa monnieri* leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: Implications in memory formation. *J Ethnopharmacol*,2011;134:55–61.
7. De la Torre J. Cerebral hemodynamics and vascular risk factors: Setting the stage for Alzheimer's disease. *J Alzheimer Dis*,2012;32:553–567.
8. Emmanuvel Rajan K, Singh HK, Parkavi A, Prisila DC. Attenuation of 1-(m-chlorophenyl) biguanide induced hippocampus-dependent memory impairment by a standardised extract of *Bacopa monnieri*. *Neurochem Res*,2011;36:2136–2144.
9. Federal Interagency Forum on Aging-Related Statistics. Older Americans. Key Indicators of Wellbeing,2012.
10. George KS, Raghunath N, Bharath MM, Muralidhara. Prophylaxis with *Bacopa monnieri* attenuates acrylamide induced neurotoxicity and oxidative damage via elevated antioxidant function. *Cent Nerv Syst Agents Med Chem*,2012 online publication.
11. Jadia P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A. Anti-Parkinsonian effects of *Bacopa monnieri*: Insights from transgenic and pharmacological *Caenorhabditis elegans* models of Parkinson's disease. *Biochem Biophys Res Commun*,2011;413:605–610.
12. Kamkaew N, Scholfield CN, Ingkaninan K, Maneesai P, Parkington HC, Tare M, Chootip K. *Bacopa monnieri* and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types. *J Ethnopharmacol*,2011;137:790–795.
13. Kamkaew N, Scholfield N, Ingkaninan K, Taepavarapruk N, Chootip K. *Bacopa monnieri* increases cerebral blood flow in rat independent of blood pressure. *Phytother Res*,2013;27:135–138.
14. Liu X, Yue R, Zhang J, Shan L, Wang R, Zhang W. Neuroprotective effects of bacoside I in ischemic brain injury. *Restor Neurol Neurosci*,2012 online publication.
15. Mathew J, Gangadharan G, Kuruvilla KP, Paulose CS. Behavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: Effect of *Bacopa monnieri*. *Neurochemical Res*,2011;36:7–16.
16. Mathew J, Paul J, Nandhu MS, Paulose CS. *Bacopa monnieri* and Bacoside-A for ameliorating epilepsy associated behavioral deficits. *FitoTerapia*,2010;81:315–322.
17. Mathew M, Subramanian M. Evaluation of the anti-amyloidogenic potential of nootropic herbal extracts in vitro. *IJPSR*,2012;3:4276–4280.
18. Mohamed A. Modafinil has the potential for addiction. *AJOB Neuroscience*,2012;3:36–38.

19. Mohanty IR, Maheshwari U, Joseph D, Deshmukh Y. *Bacopa monnieri* protects rat heart against ischaemia-reperfusion injury: role of key apoptotic regulatory proteins and enzymes. *J Pharm Pharmacol*,2010;62:1175–1184.
20. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *J Altern Complement Med*,2010;16:753–759.
21. Neale C, Camfield D, Reay J, Stough C, Scholey A. Cognitive effects of two nutraceuticals Ginseng and *Bacopa* benchmarked against modafinil: A review and comparison of effect sizes. *Br J Clin Pharmacol*,2012 online publication.
22. Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of *Bacopa monnieri*: A systematic review of randomized, controlled human clinical trials. *J Altern Complement Med*,2012;18:1–6.
23. Piyabhan P, Wetchateng T. Effects of *Bacopa monnieri* on VGLUT1 density in frontal cortex, striatum and hippocampus of schizophrenic rat model. *Eur Psychiatry*,2012 online publication.
24. Piyabhan P, Wetchateng T. Neuroprotective and cognitive enhancement effects of *Bacopa monnieri* on novel object recognition in schizophrenic rat model. *Eur Psychiatry*,2012 online publication.
25. Preethi J, Singh HK, Charles PD, Emmanuvel Rajan K. Participation of microRNA 124-CREB pathway: a parallel memory enhancing mechanism of standardised extract of *Bacopa monnieri*. *Neurochem Res*,2012;37:2167–2177.
26. Prisila DC, Singh HK, Preethi J, Rajan EK. Standardized extract of *Bacopa monnieri* (BESEB CDRI-08) attenuates contextual associative learning deficits in the aging rat's brain induced by D-galactose. *J Neurosci Res*,2012;90:2053–2064.
27. Priyanka HP, Bala P, Ankisetipalle S, Rajan ST. *Bacopa monnieri* and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF- κ B pathways in the spleen of female Wistar rats. *Neurochem Res*,2012 online publication.
28. Rastogi M, Ojha R, Prabu PC, Devi DP, Agrawal A, Dubey GP. Amelioration of age associated neuroinflammation on long term bacosides treatment. *Neurochem Res*,2012;37:869–874.
29. Rastogi M, Ojha R, Prabu PC, Devi DP, Agrawal A, Dubey GP. Prevention of age-associated neurodegeneration and promotion of healthy brain ageing in female Wistar rats by long term use of bacosides. *Biogerontology*,2012;13:183–195.
30. Rauf K, Subhan F, Abbas M, Haq I, Ali G, Ayaz M. Effect of acute and sub-chronic use of *Bacopa monnieri* on dopamine and serotonin turnover in mice whole brain. *AJPP*,2012;6:2767–2774.
31. Rusanen M, Kivipelto M, Quesenberry P Jr, Zhou J, Whitmer R. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. *Arch Intern Med*,2011;171:333–339.
32. Saini N, Singh D, Sandhir R. Neuroprotective effects of *Bacopa monnieri* in experimental model of dementia. *Neurochem Res*,2012;37:1928–1937.
33. Sandhya T, Sowjanya J, Veeresh B. *Bacopa monnieri* (L.) Wettst ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats. *Neurochem Res*,2012;37:1121–1131.
34. Saraf MK, Anand A, Prabhakar S. Scopolamine induced amnesia is reversed by *Bacopa monnieri* through participation of kinase-CREB pathway. *Neurochem Res*,2010;35:279–287.
35. Saraf MK, Prabhakar S, Khanduja KL, Anand A. *Bacopa monnieri* attenuates scopolamine-induced impairment of spatial memory in mice. *Evid Based Complement Alternat Med*,2011 electronic publication.
36. Shinomol G, Bharath M. Neuromodulatory Propensity of *Bacopa monnieri* leaf extract against 3-nitropropionic acid-induced oxidative stress: In vitro and in vivo evidences. *Neurotox Res*,2012;22:102–114.
37. Shinomol GK, Bharath MM. Pretreatment with *Bacopa monnieri* extract offsets 3-nitropropionic acid induced mitochondrial oxidative stress and dysfunctions in the striatum of prepubertal mouse brain. *Can J Physiol Pharmacol*,2012;90:595–606.
38. Shinomol GK, Muralidhara. *Bacopa monnieri* modulates endogenous cytoplasmic and mitochondrial oxidative markers in prepubertal mice brain. *Phytomedicine*,2011;18:317–326.
39. Shinomol GK, Mythri RB, Srinivas Bharath MM, Muralidhara. *Bacopa monnieri* extract offsets rotenone-induced cytotoxicity in dopaminergic cells and oxidative impairments in mice brain. *Cell Mol Neurobiol*,2012;32:455–465.
40. Shobana C, Kumar RR, Sumathi T. Alcoholic extract of *Bacopa monnieri* Linn. protects against 6-hydroxydopamine-induced changes in behavioral and biochemical aspects: A pilot study. *Cell Mol Neurobiol*,2012;32:1099–1112.
41. Singh M, Murthy V, Ramassamy C. Standardized extracts of *Bacopa monnieri* protect against MPP⁺- and paraquat-induced toxicity by modulating mitochondrial activities, proteasomal functions, and redox pathways. *Toxicol Sci*,2012;125:219–232.
42. Sumathi T, Shobana C, Christinal J, Anusha C. Protective effect of *Bacopa monnieri* on methyl mercury-induced oxidative stress in cerebellum of rats. *Cell Mol Neurobiol*,2012;32:979–987.
43. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, Paraquat and Parkinson's disease. *Environ Health Perspect*,2011;119:866–872.
44. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of *Bacopa monnieri* in Alzheimer's disease model. *J Ethnopharmacol*,2010;8(127):26–31.
45. Vollala VR, Upadhya S, Nayak S. Effect of *Bacopa monnieri* Linn. (brahmi) extract on learning and memory in rats—a behavioral study. *J Vet Behavior*,2010;5:69–74.
46. Vollala VR, Upadhya S, Nayak S. Enhancement of basolateral amygdaloid neuronal dendritic arborization following *Bacopa monnieri* extract treatment in adult rats. *Clinics (Sao Paulo)*,2011;66:663–671.